Striatal histone modifications in models of levodopa-induced dyskinesia.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, AL 35294-0017, USA.
Journal of Neurochemistry (Impact Factor: 4.24). 08/2008; 106(1):486-94. DOI: 10.1111/j.1471-4159.2008.05417.x
Source: PubMed

ABSTRACT Despite recent advances in the treatment of Parkinson disease (PD), levodopa remains the most effective and widely used therapy. A major limitation to the use of levodopa is the development of abnormal involuntary movements, termed levodopa-induced dyskinesia (LDID), following chronic levodopa treatment. Since recent studies have suggested that modifications of chromatin structure may be responsible for many long-lasting changes in brain function, we have examined post-translational modifications of striatal histones in two models of LDID: an acute murine model and a chronic macaque monkey model, both exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In the primate model, which closely resembles human LDID, we observed that chronic levodopa and the appearance of LDID was associated with marked deacetylation of histone H4, hyperacetylation and dephosphorylation of histone H3, and enhancement of the phosphorylation of extracellular signal-regulated kinase (ERK). In the murine model of acutely rather than chronically induced LDID, dopamine depletion and levodopa treatment also induced deacetylation of histone H4 and phosphorylation of ERK, but histone H3 exhibited decreased trimethylation and reduced rather than enhanced acetylation. These data demonstrate striking changes in striatal histones associated with the induction of LDID in both animal models. The pattern of changes observed, as well as the behavioral features, differed in the two models. However, both models exhibit marked deacetylation of histone H4, suggesting that inhibitors of H4 deacetylation may be useful in preventing or reversing LDID.


Available from: Erwan Bezard, Sep 03, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently, 5-hydroxymethyl cytosine (5hmC) was identified in higher organisms as a novel epigenetic modification factor, and was found to be substantially enriched in the central nervous system relative to many other tissues and cell types. Additionally, epigenetic modifications are markedly involved in many neurological disorders. However, the precise role of 5hmC in the brain and neurological diseases remains elusive. To reveal its functional role, a general screen of its spatial and temporal distribution was proposed as being a reasonable starting investigation. Here, we found that 5hmC was widely distributed in the cerebral cortex, striatum, hippocampus, cerebellum, and the brain stem. At the cellular level, 5hmC was widely expressed in neurons and astrocytes even probably the majority of glial cells. Further, the content of 5hmC in different brain regions was inconsistent. Moreover, the pattern of 5hmC in the regions of the whole rat brain was highly susceptible to age-associated modifications. We also found similar phenomena in the striatum, which had not been previously studied. Also, unlike other brain regions, for example in the cerebellum and granulosa cells, 5hmC also appeared to display specific expression in these tissues. However, we didn't obtain the expected result that 5hmC will be increased in 6-hydroxydopamine-induced models of Parkinson's disease with regard the preliminary exploration of 5hmC in these models. Our results suggest that in rats and other mammals, 5hmC likely plays an important role in the brain and is associated with neural development and aging in different areas of the brain.
    Neurochemical Research 02/2015; 40(4). DOI:10.1007/s11064-015-1515-3 · 2.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background ΔFosB is a surrogate marker of L-Dopa-induced dyskinesia (LID), the unavoidable disabling consequence of Parkinson’s disease (PD) L-dopa long-term treatment. However, the relationship between the electrical activity of FosB/ΔFosB-expressing neurons and LID manifestation is unknown. Methods We used the Daun02 prodrug-inactivation method associated with lentiviral expression of ß-galactosidase under the control of the FosB promoter to investigate a causal link between the activity of FosB/ΔFosB-expressing neurons and dyskinesia severity in both rat and monkey models of PD and LID. Whole-cell recordings of medium spiny neurons (MSNs) were performed to assess the effects of Daun02 and daunorubicin on neuronal excitability Results We first show that daunorubicin, the active product of Daun02 metabolism by ß-galactosidase, decreases the activity of MSNs in rat brain slices, and that Daun02 strongly decreased the excitability of rat MSNs primary cultures expressing ß-galactosidase upon D1 dopamine receptor stimulation. We then demonstrate that the selective, and reversible, inhibition of FosB/ΔFosB-expressing striatal neurons with Daun02 decreases the severity of LID while improving the beneficial effect of L-Dopa. Conclusions These results establish that FosB/ΔFosB accumulation ultimately results in altered neuronal electrical properties sustaining maladaptive circuits leading not only to LID, but also to a blunted response to L-Dopa. These findings further reveal that targeting dyskinesia can be achieved without reducing the antiparkinsonian properties of L-Dopa when specifically inhibiting FosB/ΔFosB-accumulating neurons.
    Biological Psychiatry 07/2014; DOI:10.1016/j.biopsych.2014.07.007 · 9.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (PD) is the second most common age-related neurodegenerative disease, but its pathogenesis is not fully understood. The selective neuronal cell death in PD has been considered to result from a complex interaction between genetic and environmental factors, but the nature of the relationship between the two chief modifiers remains to be elucidated. There is a growing body of evidence supporting the role of epigenetics in the development and progression of many neurodegenerative diseases including PD. Epigenetic modification refers to changes in gene expression or function without changes in DNA sequence, which mainly includes DNA methylation, post-modifications of histone, and non-coding RNAs. In this review, we will focus on the abnormal epigenetic modifications involved in the pathogenesis of PD and their implications for the development of future diagnostic and therapeutic strategies. Copyright © 2014 Elsevier B.V. All rights reserved.
    Journal of the Neurological Sciences 12/2014; 349(1-2). DOI:10.1016/j.jns.2014.12.017 · 2.26 Impact Factor